Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243618 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL15988125 | 0.89 | CHRM2 (0.38) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL3248189 | 0.88 | NR1H2 (0.34) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL584822 | 0.86 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL585463 | 0.86 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL5569326 | 0.84 | ATM (0.36) | ATMDPP4DPP8DPP9 | |
| SCHEMBL3245499 | 0.82 | HSD11B1 (0.33) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL27441852 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL24463662 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CYP1A2POLB | |
| SCHEMBL20135092 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159416-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | CHRM2 469/4885CHRM1 617/4885CHRM3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.